Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nonmyeloablative Stem Cell Transplantation for Severe Congenital Anemias
NCT00061568Phase 2Active, not recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jul 2004
- Primary completion
- Jan 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of peripheral blood stem cells, alemtuzumab, sirolimus in sickle cell disease (SCD), beta thalassemia, sponsored by National Heart, Lung, and Blood Institute. Started Jul 2004; status: active, not recruiting.
02
Drugs
peripheral blood stem cellsalemtuzumabsirolimus
03
Conditions
sickle cell disease (SCD)beta thalassemia
Beyond the preview
Go deeper on NCT00061568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00061568.